Topic: infectious disease
“Agreeing to refund the used doses of Dengvaxia would imply that the vaccine is ineffective, which is not the case,” said Sanofi.
The Philippine DOH is now officially asking Sanofi to refund some $39 million for used Dengvaxia doses as well.
The WHO stopped classifying Zika as an emergency in late 2016, but Takeda has pressed ahead with its program, winning an FDA fast-track designation.
After failing a phase 2 in solid-organ transplant patients, the CMV vaccine failed in hematopoietic cell transplant recipients too.
Here is some other vaccine news of note for the week.
Moderna unveiled two phase 1 prophylactic vaccine programs and a new Chikungunya antibody candidate at JPM.
An investment fund formed by J.P. Morgan and the Gates Foundation, Global Health Investment Fund led Themis' €10 million series C.
Sanofi's recent loss in C. diff is a win for Pfizer and Valneva, which boast their own late-stage candidates, according to GlobalData.
More than 70 mothers in the Philippines whose children were vaccinated against dengue filed a criminal complaint against government and company officials.
As Philippines lawmakers continue probing the country's now-controversial dengue immunization program, a former president has spoken up to defend it.